Roche Reports P-II/III (SKYSCRAPER-06) Trial Data of Tiragolumab to Treat Non-Squamous Non-Small Cell Lung Cancer
Shots:
- The P-II/III (SKYSCRAPER-06) study assesses tiragolumab + Tecentriq & CT vs Keytruda & CT as a 1L treatment of locally advanced, inoperable or metastatic non-squamous NSCLC patients (n=542)
- The study did not reach its 1EPs of PFS & OS (immature), depicting a reduced efficacy among the ITT population due to which the patients & investigators will be unblinded and the trial will be terminated. Data will be highlighted at future conferences and shared with health authorities
- The company will make necessary changes in the tiragolumab program based on these outcomes. Further P-III studies, evaluating different treatment options & indications from SKYSCRAPER-06, are underway
Ref: Roche | Image: Roche
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
